HPV VACCINE AND AIN Palefsky NEJM 2011 n=602 MSM 16-26y qhpv = vaccine against HPV 6, 11, 16 and 18 vs placebo They analyzed ITT and per protocol.
|
|
- Aubrey Gordon
- 6 years ago
- Views:
Transcription
1 ANAL CANCER Updated Mar 2017 by Doreen Ezeife, PGY-5 resident University of Calgary Reviewed by Dr. Lee-Ying (Staff Medical Oncologist, University of Calgary), Dr. Kzyzanowska (Staff Medical Oncologist, University of Toronto) and Dr. Cummings (Staff Radiation Oncologist, University of Toronto) DISCLAIMER: The following are study notes compiled by the above PGY-5 medical oncology resident and reviewed by a staff medical oncologist. They reflect what we feel is relevant knowledge for graduating medical oncology residents preparing for their final examination. The information has not been surveyed or ratified by the Royal College. A) PUBLIC HEALTH EPIDEMIOLOGY - Incidence: Rare, cases in Canada per year(1) - Mortality: Less than 100 deaths in Canada per year RISK FACTORS - Environmental/Chemical/Infections: o HPV (Serotypes 16 and 18) mainly HPV 16 o History of anal warts o History of cervical, vulvar or vaginal cancer o History of multiple sexual partners, anal-receptive intercourse and sexually transmitted infections o Immunosuppression (HIV, organ transplant) o Cigarette smoking o Chronic inflammation/fistulas in the context of inflammatory bowel disease - Genetic: o None known PREVENTION & SCREENING - Prevention: o Interventions to reduce HPV risk Vaccination against HPV (2) the quadrivalent HPV vaccine (HPV-6, 11, 16 and 18) reduced the rate of anal intraepithelial neoplasia in males (Palefsky et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. NEJM 2011;365: ) HPV VACCINE AND AIN Palefsky NEJM 2011 n=602 MSM 16-26y qhpv = vaccine against HPV 6, 11, 16 and 18 vs placebo They analyzed ITT and per protocol. ITT per protocol Efficacy 50.3% 77% Risk persistent infection 59.4% 94.9% qhvp ITT/pprot Placebo ITT/pprot Rate AIN/100 persons-years 13/4 7.5/8.9 Safe sex interventions Male circumcision (3)
2 o Smoking Cessation - Screening: o No specific Canadian guidelines o Medford and Salit (4) strongest recommendation for screening for men with HIV who have sex with men. Also recommend for all men and women with HIV, women with genital dysplasia or cancers, anyone with perianal high-grade lesions, and recipients of solid organ transplants. o Options for screening include: Anal Papanicolaou test for cytology and/or HPV testing Digital anal exam High resolution anoscopy with staining with vinegar or Lugol s iodine B) PRESENTATION & DIAGNOSIS SYMPTOMS & SIGNS - Common Symptoms: o anal itching, discharge, bleeding o pain or pressure in the anal area that is not relieved by a bowel movement o change in bowel habits: changes to the caliber, constipation, diarrhea or alternating between constipation and diarrhea - Common Signs: o lump or swelling in the anal area o enlarged lymph nodes in the groin or anal area INVESTIGATIONS - Physical Exam o Include digital rectal exam and palpation of inguinal lymph nodes o Pelvic exam for all women with cervical Pap smear - Laboratory o Routine bloodwork, HIV, hepatitis screen - Diagnostic Imaging: o Pelvic MRI o CT chest, abdomen and pelvis - Diagnostic Procedures: o Biopsy PATHOLOGY & MOLECULAR BIOLOGY - Most commonly squamous cell carcinoma and variants (cloacogenic, basaloid, transitional) - Adenocarcinoma is managed like rectal cancer - Anal melanoma also accounts for a small percentage of anal cancers - Lymphatic drainage to peri-rectal, inguinal, and internal iliac nodes STAGING AJCC 7 th Edition
3 C) TREATMENT LOCALIZED AND LOCALLY ADVANCED(5) - Consider surgery alone with a wide local excision for stage 0 (carcinoma in situ) and stage I (T1N0) - wide local excision should only be considered for stage I if negative margins can be achieved and continence can be preserved. - Consider primary chemoradiotherapy (as described for stage II-III disease) if sphincter preservation is not possible with wide local excision. - Stage II-III should be treated with concurrent chemoradiation: o Allows for sphincter preservation, but no overall survival benefit, as per the trials below o Gy/25-35# to the perineum and regional lymph nodes plus o 5-FU 4000mg/m2 over 4 days during week 1 and possibly week 5 plus o mitomycin 10mg/m2 IV d1 and 29 or cisplatin 75mg/m2 d1 and 29 if mitomycin contraindicated - Consider an RT boost for stage IIIB disease - Consider abdominoperineal resection for salvage treatment of residual disease - Special considerations o HIV-infected and immunosuppressed (i.e. organ transplant) patients should be managed the same as non-immunosuppressed patients if CD4 count > Follow-up o Exam at 8-12 weeks post-treatment then q3-6 months for 5 years - Prognosis: o 5-year OS Localized = 80% Regional = 50% o Poor prognostic features: T4 N2-3 - Important Phase III Clinical Trials:
4 ACT 1 Trial (UK-CCCR) Epidermoid anal cancer: Results from the UK-CCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil and mitomycin. UK CCCR Anal Cancer Working Party. Lancet, Regimen Radiation (40-45Gy +/- boost) with or without concurrent 5-FU (1000mg/m2/d d1-4 or 750mg/m2/d d1-5) and mitomycin C (12mg/m2 d1) Primary Endpoint Local failure rate Inclusion/Exclusion Included everyone except T1N0 Patients with metastatic disease were included as the primary endpoint was local control Size (N) 585 Results Local control: Significantly improved with CRT (39%) compared to RT alone (61%) RR 0.54 (CI ) Survival: No difference in all-cause mortality but improved diseasespecific mortality with CRT (28%) compared to RT alone (39%) Toxicity Increased early toxicity with CRT (neutropenia, rash, diarrhea) Similar late toxicity profile Similar morbidity with salvage surgery when necessary Conclusion 5-FU and mitomycin should be added concurrently with radiation to improve colostomy-free survival Other Comments Surgery for incomplete response at 6 weeks EORTC Trial Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advance anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. H. Bartelink et al. JCO Regimen Radiation (45Gy +/- boost) with or without concurrent 5-FU and mitomycin C Primary Endpoint Local failure rate (colostomy-free survival) Inclusion/Exclusion Included T3-4N0-3 or T1-2N1-3 Size (N) 110 Results 5-yr colostomy-free survival: CRT reduced absolute rate of colostomy by 32% (p = 0.002) Survival: No difference in survival Toxicity Similar severe side-effects Increased rate of anal ulcers in CRT group Conclusion 5-FU and mitomycin should be added concurrently with radiation to improve colostomy-free survival Other Comments Surgery for incomplete response at 6 weeks
5 RTOG Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. M. Flam et al. JCO Regimen Radiation ( Gy) and 5-FU (1000mg/m2/d) with or without mitomycin C (10mg/m2) For residual tumor: additional radiation (9Gy) and 5-FU and cisplatin (100mg/m2) Primary Endpoint Local failure rate (colostomy-free survival) Inclusion/Exclusion Any T or N No metastatic disease Size (N) 310 Results 4-y colostomy rate: Mitomycin reduced absolute rate of colostomy by 13% (p = 0.002) 4-y disease-free survival: Mitomycin improved DFS by 22% (73% vs 51%, p = ) Survival: No difference in survival Salvage therapy: 50% complete response to salvage therapy if required Toxicity Increased grade 4 and 5 toxicity in mitomycin group Conclusion Mitomycin should be added concurrently with radiation and 5-FU to reduce the rate of colostomy and improve disease-free survival Intergroup RTOG Fluorouracil, mitomycin, and radiotherapy vs. fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial. J. Ajani et al. JAMA Regimen 1. Radiation (45-59Gy) and 5-FU (1000mg/m2/d d1-4 and 29-32) with mitomycin C (10mg/m2 d1 and 29) 2. Induction chemotherapy 5-FU (1000mg/m2/d, d1-4, 29-32) and cisplatin (75mg/m2, d1 and 29) followed by radation (45-59Gy) starting d57 with 5-FU (1000mg/m2/d, d57-60 and 85-88) and cisplatin (75mg/m2, d57 and 85) Primary Endpoint 5-y DFS Inclusion/Exclusion T2-4, any N No metastatic disease Size (N) 682 Results No difference in DFS or OS although trend towards worse outcomes for cisplatin group Worse colostomy rate in cisplatin group (19%) compared to mitomycin group (10%), p = 0.02 Toxicity Similar toxicity profile Conclusion Cisplatin-based CRT was not superior to mitomycin-based CRT Rate of colostomy was higher with cisplatin-based CRT
6 ACT II Trial Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, openlabel, 2 2 factorial trial. RD James et al. Lancet Oncol Regimen 1. Radiation (50.4Gy/28#) and 5-FU (1000mg/m2/d d1-4 and 29-32) with mitomycin C (12mg/m2 d1), no maintenance 2. Radiation and 5-FU (1000mg/m2/d d1-4 and 29-32) with cisplatin (60mg/m2 d1 and 29), no maintenance 3. Radiation and 5-FU (1000mg/m2/d d1-4 and 29-32) with mitomycin C (12mg/m2 d1) + maintenance 5-FU (1000mg/m2/d d71-74 and d92-95) and cisplatin (60mg/m2 d71 and d92) 4. Radiation and 5-FU (1000mg/m2/d d1-4 and 29-32) with cisplatin (60mg/m2 d1 and 29) + maintenance 5-FU and cisplatin Primary Endpoint Complete response Acute toxic effects Progression-free survival Inclusion/Exclusion Any T and N No metastatic disease Size (N) 940 Results All groups essentially identical Toxicity Similar toxicity profile Conclusion Mitomycin-based CRT is still the standard of care Maintenance chemotherapy did not offer additional benefit Other Comments Inferior results of the RTOG trial for the cisplatin arm could be related to the delay in radiation because of the initial induction chemotherapy. - Other Important Published Data: o Systematic review by Spithoff et al in 2014 confirmed best evidence for radiation plus 5- FU and mitomycin(6). METASTATIC - Bottom Line General Approach:(7,8) o Currently no randomized data to support decision o Consider resection for oligometastatic disease o Cisplatin 75mg/m2 and 5-FU 4000mg/m2 over 4 days every 28 days remains the most commonly reported regimen o Weekly cisplatin (for less fit) - Prognosis: o Not well understood, case series reports 9-24 months - Future data: o Current trial of cisplatin plus 5-FU vs carboplatin plus weekly paclitaxel is underway OTHER HPV negative SCC AC do not respond to treatment and have TP53 mutations Meulendijks BJC 2015 N=107 locally adv SCC AC that received RT+/- chemo % pts HPV/p16 status 3y locoreg control (s) TP53 mutation (s) 87% HPV+/p16+ 82% 6% 9% HPV-/p16-75% 4% HPV-/p16+ 15% 80%
7 D) REFERENCES 1. Canadian Cancer Society. Canadian Cancer Statistics 2015: Special topic: Predictions of the future burden of cancer in Canada. 2015; 2. Canada PHA of. Update on the recommended Human Papilllomavirus (HPV) vaccine immunization schedule Jul. 3. Castellsagué X, Bosch FX, Muñoz N, Meijer CJLM, Shah K V, de Sanjose S, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med Apr 11;346(15): Medford RJ, Salit IE. Anal cancer and intraepithelial neoplasia: epidemiology, screening and prevention of a sexually transmitted disease. CMAJ Feb 3;187(2): Spithoff K, Cummings B, Jonker D, Biagi J. Gastrointestinal Cancer Disease Site Group. Management of squamous cell cancer of the anal canal Spithoff K, Cummings B, Jonker D, Biagi JJ. Chemoradiotherapy for squamous cell cancer of the anal canal: a systematic review. Clin Oncol (R Coll Radiol) Aug;26(8): Eng C, Chang GJ, You YN, Das P, Rodriguez-Bigas M, Xing Y, et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget Nov 30;5(22): Khawandanah M, Baxley A, Pant S. Recurrent metastatic anal cancer treated with modified paclitaxel, ifosfamide, and cisplatin and third-line mitomycin/cetuximab. J Oncol Pharm Pract Jun;21(3):232 7.
ANAL CANCER Updated May 2016 by Dr. Daniel Yokom (PGY-5 Medical Oncology Resident, University of Toronto)
ANAL CANCER Updated May 2016 by Dr. Daniel Yokom (PGY-5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Lee-Ying (Staff Medical Oncologist, University of Calgary), Dr. Kzyzanowska (Staff
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationDepartment of Radiotherapy, Pt. BDS PGIMS, Rohtak, Haryana, India
Bharti et al., IJPSR, 2010; Vol. 1 (11): 169-173 ISSN: 0975-8232 IJPSR (2010), Vol. 1, Issue 11 (Research Article) Received on 29 September, 2010; received in revised form 21 October, 2010; accepted 26
More informationBottoms UP HIV and Anal Cancer from Screening to Prevention
Bottoms UP HIV and Anal Cancer from Screening to Prevention Paul MacPherson PhD, MD, FRCPC Associate Professor Division of Infectious Diseases University of Ottawa The New Reality Normal or near-normal
More informationCancer in the LGBTQ Community. Katie Imborek, MD Clinical Assistant Professor University of Iowa Department of Family Medicine
+ Cancer in the LGBTQ Community Katie Imborek, MD Clinical Assistant Professor University of Iowa Department of Family Medicine + Objectives Discuss the possible reasons that LGBTQ people have a disproportionate
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Prague July 2016 State of the art: Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre Aim to discuss Background The trials
More informationDr Mark Saunders Christie Hospital and Paterson Institute of Cancer Research. Anal cancer chemoradiotherapy
Dr Mark Saunders Christie Hospital and Paterson Institute of Cancer Research Anal cancer chemoradiotherapy No disclosures to declare Anal tumours - pathology SCC Basaloid* Cloacogenic (transitional)* Adenocarcinoma
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationCombined Modality Treatment of Anal Carcinoma
Combined Modality Treatment of Anal Carcinoma F. ROELOFSEN, a H. BARTELINK b a Bethesda Krankenhaus, Essen, Germany; b The Netherlands Cancer Institute/Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, The
More informationPrognostic factors in squamous cell anal cancers
Prognostic factors in squamous cell anal cancers Zainul Abedin Kapacee Year 4-5 Intercalating Medical Student, University of Manchester Dr. Shabbir Susnerwala, Mr. Nigel Scott Dr. Falalu Danwata, Dr. Marcus
More informationUPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER
UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: James RD, Glynne-Jones R, Meadows HM, et al.
More informationHIV-infected men and women. Joel Palefsky, M.D. University of California, San Francisco
Anal cytology and anal cancer in HIV-infected men and women. Joel Palefsky, M.D. University of California, San Francisco April 10, 2010 Disclosures Merck and Co: Research grant support, advisory boards
More informationCarcinoma del Canale Anale. Approcci RadioChemioterapici. Antonino De Paoli.. Oncologia Radioterapica, CRO Aviano.
Carcinoma del Canale Anale Approcci RadioChemioterapici Antonino De Paoli.. Oncologia Radioterapica, CRO Aviano. Anal Cancer Epidemiology and Risk Factors Uncommon Disease; 2-4% of all GI Tumors Increasing
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationGynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.
Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year
More informationTrimodality Therapy for Muscle Invasive Bladder Cancer
Trimodality Therapy for Muscle Invasive Bladder Cancer Brita Danielson, MD, FRCPC Radiation Oncologist, Cross Cancer Institute Assistant Professor, Department of Oncology University of Alberta Edmonton,
More informationAbout anal cancer. Incorporating hospital and community health services, teaching and research
About anal cancer Incorporating hospital and community health services, teaching and research The Homerton Anal Neoplasia Service is a referral centre that provides a screening and treatment service for
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER VULVAR Last Revision Date July 2015 1 Site Group: Gynecologic Cancer Vulvar Author: Dr. Stephane Laframboise 1. INTRODUCTION
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationSeptember 10, Dear Dr. Clark,
September 10, 2015 Peter E. Clark, MD Chair, NCCN Bladder Cancer Guidelines (Version 2.2015) Associate Professor of Urologic Surgery Vanderbilt Ingram Cancer Center Nashville, TN 37232 Dear Dr. Clark,
More informationHPV-related papillomatous-condylomatous lesions in female anogenital area
HPV-related papillomatous-condylomatous lesions in female anogenital area Theo Panoskaltsis MD, FRCOG, CCST (UK) Epidemiology Anal cancer is increasing in both men and women Groups at risk: - HIV (+)
More informationARROCase: Locally Advanced Endometrial Cancer
ARROCase: Locally Advanced Endometrial Cancer Charles Vu, MD (PGY-3) Faculty Advisor: Peter Y. Chen, MD, FACR Beaumont Health (Royal Oak, MI) November 2016 Case 62yo female with a 3yr history of vaginal
More informationMini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background
Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016 Background Mostly adenocarcinoma (scc possible, but treated like anal cancer) 39, 220 cases annually Primary treatment: surgery
More informationRadiotherapy for rectal cancer. Karin Haustermans Department of Radiation Oncology
Radiotherapy for rectal cancer Karin Haustermans Department of Radiation Oncology O U T L I N E RT with TME surgery? Neoadjuvant or adjuvant RT? 5 x 5 Gy or long-course CRT? RT with new drugs? Selection
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Anal Cancer Valencia May 2018 Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures: last 5 years Speaker: Roche, Merck Serono,
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND
More informationand treating joins with the top of canal). at risk for cervical carcinomas, cervix.
CERVICAL CANCER Worldwide, cervical cancer is twelfth most common and the fifth most deadly cancer in women. It affects about 16 per 100,000 women per year and kills about 9 per 100,000 per year. Cervical
More informationBladder Preservation Strategies for Muscle Invasive Bladder Cancer
Bladder Preservation Strategies for Muscle Invasive Bladder Cancer Jeff M. Michalski, MD, MBA, FACR, FASTRO The Carlos A. Perez Distinguished Professor of Radiation Oncology Department of Radiation Oncology
More informationNavigators Lead the Way
RN Navigators Their Role in patients with Cancers of the GI tract Navigators Lead the Way Nurse Navigator Defined Nurse Navigator A clinically trained individual responsible for the identification and
More informationONLINE CONTINUING EDUCATION ACTIVITY
ONLINE CONTINUING EDUCATION ACTIVITY Take free quizzes online at acsjournals.com/ce ARTICLE TITLE: Anal Cancer: Current Standards in Care and Recent Changes in Practice CONTINUING MEDICAL EDUCATION ACCREDITATION
More informationPreoperative or Postoperative Therapy for the Management of Patients with Stage II or III Rectal Cancer
Evidence-Based Series 2-4 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Preoperative or Postoperative Therapy for the Management of Patients with
More informationESMO Preceptorship Programme, Colorectal Cancer, Vienna
State of the art multimodal treatment of anal cancer ESMO Preceptorship Programme, Colorectal Cancer, Vienna Rob Glynne-Jones Mount Vernon Centre for Cancer Treatment Disclosures: last 5 years Speaker:
More informationAnal Carcinoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2016 NCCN.org Continue Version 2.2016, 04/27/16 National Comprehensive Cancer Network, Inc. 2016, All rights reserved. The NCCN
More informationHPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines. Anal Carcinoma. Version NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2013 NCCN.org Continue Version 2.2013,12/11/12 National Comprehensive Cancer Network, Inc. 2012, All rights reserved. The NCCN
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationGuideline for the Management of Vulval Cancer
Version History Guideline for the Management of Vulval Cancer Version Date Brief Summary of Change Issued 2.0 20.02.08 Endorsed by the Governance Committee 2.1 19.11.10 Circulated at NSSG meeting 2.2 13.04.11
More informationRECTAL CANCER CLINICAL CASE PRESENTATION
RECTAL CANCER CLINICAL CASE PRESENTATION Francesco Sclafani Medical Oncologist, Clinical Research Fellow The Royal Marsden NHS Foundation Trust, London, UK esmo.org Disclosure I have nothing to declare
More informationAnal Carcinoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version April 20, 2017 NCCN.org. Continue
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 2.2017 April 20, 2017 NCCN.org Continue Version 2.2017, 04/20/17 National Comprehensive Cancer Network, Inc. 2017, All rights reserved.
More informationHPV & RELATED DISEASES
GAY MEN, HPV & ANAL CANCER THEBOTTOMLINE.ORG.AU HPV & RELATED DISEASES WHAT IS HPV? The Human Papilloma Virus (HPV) is not one virus, but a family of about 200 different ones that cause common warts, genital
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationManagement of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT
Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center Disclosure Consulting
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationHuman Papillomavirus (HPV) in Patients with HIV.
Human Papillomavirus (HPV) in Patients with HIV www.hivguidelines.org Purpose of the Guideline Increase the numbers of NYS residents with HIV who are screened for HPV-related dysplasia and managed effectively.
More informationCERVICAL CANCER FACTSHEET. What is cervical cancer?
CERVICAL CANCER FACTSHEET What is cervical cancer? ENGAGe is releasing a series of factsheets to raise awareness of gynaecological cancers and to support its network to work at a grassroots level. Take-up
More informationPreoperative adjuvant radiotherapy
Preoperative adjuvant radiotherapy Dr John Hay Radiation Oncology Program BC Cancer Agency Vancouver Cancer Centre The key question for the surgeon Do you think that this tumour can be resected with clear
More informationRadiation Oncology MOC Study Guide
Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationCan we omit prophylactic inguinal nodal irradiation in anal cancer patients?
Original Article Radiat Oncol J 215;33(2):83-88 http://dx.doi.org/1.3857/roj.215.33.2.83 pissn 2234-19 eissn 2234-3156 Can we omit prophylactic inguinal nodal irradiation in anal cancer patients? Hakyoung
More informationConcurrent chemoradiation with volumetric modulated Arc therapy of patients treated for anal cancer acute toxicity and treatment outcome
Original Article Concurrent chemoradiation with volumetric modulated Arc therapy of patients treated for anal cancer acute toxicity and treatment outcome Kaloyan Yordanov, Simona Cima, Antonella Richetti,
More information17 th ESO-ESMO Masterclass in clinical Oncology
17 th ESO-ESMO Masterclass in clinical Oncology Cervical and endometrial Cancer Cristiana Sessa IOSI Bellinzona, Switzerland Berlin, March 28 th, 2018 Presenter Disclosures None Cervical Cancer Estimated
More informationRadiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK
Lead Group Log Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Cervical Cancer treatment Treatment planning should be made on a multidisciplinary
More informationGynecologic Malignancies. Kristen D Starbuck 4/20/18
Gynecologic Malignancies Kristen D Starbuck 4/20/18 Outline Female Cancer Statistics Uterine Cancer Adnexal Cancer Cervical Cancer Vulvar Cancer Uterine Cancer Endometrial Cancer Uterine Sarcoma Endometrial
More informationHPV, Cervical Dysplasia and Cancer
FACTSHEET HPV, Cervical Dysplasia and Cancer Summary Cervical dysplasia is an abnormal change in the cells of the cervix in the uterus. Early changes, called low-grade lesions by doctors, may persist and
More informationUpdated Apr 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
Local Esophageal Cancer Summary Updated Apr 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Reviewed by Dr. Yoo-Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer Centre, University
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationMANAGEMENT OF LOCALLY ADVANCED OROPHARYNGEAL CANER: HPV AND NON-HPV MEDIATED CANCERS
MANAGEMENT OF LOCALLY ADVANCED OROPHARYNGEAL CANER: HPV AND NON-HPV MEDIATED CANCERS Kyle Arneson, MD PhD Avera Medical Group Radiation Oncology Avera Cancer Institute 16 th Annual Oncology Symposium September
More informationVaginal intraepithelial neoplasia
Vaginal intraepithelial neoplasia The terminology and pathology of VAIN are analogous to those of CIN (VAIN I-III). The main difference is that vaginal epithelium does not normally have crypts, so the
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationNCCN Clinical Practice Guidelines in Oncology. Anal Carcinoma V Continue.
Clinical in Oncology V.1.2010 Continue www.nccn.org Panel Members * Paul F. Engstrom, MD/Chair Peter C. Enzinger, MD David P. Ryan, MD Fox Chase Cancer Center Dana-Farber/Brigham and Women s Cancer Center
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationSMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)
SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Desiree Hao (Staff Medical Oncologist, University of Calgary) and Dr.
More informationCHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre
CHEMO-RADIOTHERAPY FOR BLADDER CANCER Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre AIMS Muscle invasive disease Current Gold-Standard Rationale behind Chemo-Radiotherapy
More informationPenis Cancer. What is penis cancer? Symptoms. Patient Information. Pagina 1 / 9. Patient Information - Penis Cancer
Patient Information English 31 Penis Cancer The underlined terms are listed in the glossary. What is penis cancer? Cancer is abnormal cell growth in the skin or organ tissue. When this cell growth starts
More informationRadiotherapy for Rectal Cancer. Kevin Palumbo Adelaide Radiotherapy Centre
Radiotherapy for Rectal Cancer Kevin Palumbo Adelaide Radiotherapy Centre Overview CRC are common (3 rd commonest cancer) rectal Ca approx 25-30% of all CRC. Presentation PR bleeding: beware attributing
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More information8. The polyp in the illustration can be described as (circle all that apply) a. Exophytic b. Pedunculated c. Sessile d. Frank
Quiz 1 Overview 1. Beginning with the cecum, which is the correct sequence of colon subsites? a. Cecum, ascending, splenic flexure, transverse, hepatic flexure, descending, sigmoid. b. Cecum, ascending,
More informationPancreatic Adenocarcinoma
Pancreatic Adenocarcinoma AProf Lara Lipton 28 April 2018 Percentage alive 5 years after diagnosis for men and women Epidemiology 6% of cancer related deaths worldwide 4 th highest cause of cancer death
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationPenis Cancer. What is penis cancer? Symptoms. Patient Information. Pagina 1 / 9. Patient Information - Penis Cancer
Patient Information English 31 Penis Cancer The underlined terms are listed in the glossary. What is penis cancer? Cancer is abnormal cell growth in the skin or organ tissue. When this cell growth starts
More informationHYPERTHERMIA in CERVIX and VAGINA CANCER. J. van der Zee
HYPERTHERMIA in CERVIX and VAGINA CANCER J. van der Zee ESTRO 2006 Deep hyperthermia in Rotterdam HYPERTHERMIA in CERVIX and VAGINA CANCER ESTRO 2006 Hyperthermia and radiotherapy in primary advanced cervix
More informationWhere are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
More informationThe PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationUpdate on Anal HPV. Medical Management of AIDS. December 9, Joel Palefsky Department of Medicine University of California, San Francisco
Update on Anal HPV Medical Management of AIDS December 9, 2017 Joel Palefsky Department of Medicine University of California, San Francisco Disclosures Merck and Co- research and travel support Antiva
More informationPathology of the Cervix
Pathology of the Cervix Thomas C. Wright Pathology of the Cervix Topics to Consider Burden of cervical cancer 1 Invasive Cervical Cancer Cervical cancer in world Second cause of cancer death in women Leading
More informationCervical cancer presentation
Carcinoma of the cervix: Carcinoma of the cervix is the second commonest cancer among women worldwide, with only breast cancer occurring more commonly. Worldwide, cervical cancer accounts for about 500,000
More informationGynecological Cancers
Gynecological Cancers Outline Ovarian Cancer Uterine (Endometrial) Cancer Cervical Cancer Vulvar Cancer Vaginal Cancer Overian Cancer Ovarian cancer is cancer that forms in the tissue of the ovary and
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More informationSCCPS Scientific Committee Position Paper on HPV Vaccination
SCCPS Scientific Committee Position Paper on HPV Vaccination Adapted from Joint Statement (March 2011) of the: Obstetrical & Gynaecological Society of Singapore (OGSS) Society for Colposcopy and Cervical
More informationHypofractionated RT in Cervix Cancer. Anuja Jhingran, MD
Hypofractionated RT in Cervix Cancer Anuja Jhingran, MD Hypofractionated RT in Cervix Cancer: Clinicaltrials.gov 919 cervix trials 134 hypofractionated RT trials Prostate, breast, NSCLC, GBM 0 cervix trials
More informationHPV and Head and Neck Cancer: What it means for you and your patients
HPV and Head and Neck Cancer: What it means for you and your patients Financial Disclosure: None November 8, 2013 Steven J. Wang, MD Associate Professor Department of Otolaryngology-Head and Neck Surgery
More informationCervical Cancer 3/25/2019. Abnormal vaginal bleeding
Cervical Cancer Abnormal vaginal bleeding Postcoital, intermenstrual or postmenopausal Vaginal discharge Pelvic pain or pressure Asymptomatic In most patients who are not sexually active due to symptoms
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationSelf-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
More informationMEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY
MEDICAL POLICY SUBJECT: HIGH RESOLUTION ANOSCOPY PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationAn update on the Human Papillomavirus Vaccines. I have no financial conflicts of interest. Case 1. Objectives 10/26/2016
An update on the Human Papillomavirus Vaccines Karen Smith-McCune Professor, UCSF Department of Obstetrics, Gynecology and Reproductive Sciences John Kerner Endowed Chair I have no financial conflicts
More informationEstimated New Cancers Cases 2003
Harvard-MIT Division of Health Sciences and Technology HST.071: Human Reproductive Biology Course Director: Professor Henry Klapholz Estimated New Cancers Cases 2003 Images removed due to copyright reasons.
More informationCase Report A Regimen of Taxol, Ifosfamide, and Platinum for Recurrent Advanced Squamous Cell Cancer of the Anal Canal
Hindawi Publishing Corporation Chemotherapy Research and Practice Volume 2011, Article ID 163736, 6 pages doi:10.1155/2011/163736 Case Report A Regimen of Taxol, Ifosfamide, and Platinum for Recurrent
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More information